Case Series of Patients with Coronavirus Disease 2019 Pneumonia Treated with Hydroxychloroquine
The efficacy of hydroxychloroquine (HCQ) therapy, a previous candidate drug for coronavirus disease 2019 (COVID-19), was denied in the global guideline. The risk of severe cardiac events associated with HCQ was inconsistent in previous reports. In the present case series, we show the tolerability of...
Main Authors: | Tomohiro Tanaka, Masaki Okamoto, Norikazu Matsuo, Yoshiko Naitou-Nishida, Takashi Nouno, Takashi Kojima, Yuuya Nishii, Yoshihiro Uchiyashiki, Hiroaki Takeoka, Yoji Nagasaki |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2023-03-01
|
Series: | Medicina |
Subjects: | |
Online Access: | https://www.mdpi.com/1648-9144/59/3/541 |
Similar Items
-
Use of chloroquine and hydroxychloroquine in COVID-19 patients: A dilemma
by: Archana Bhatia, et al.
Published: (2022-01-01) -
The role of hydroxychloroquine in COVID-19: Where do we stand?
by: Ranjit Mohan Anjana, et al.
Published: (2020-01-01) -
Successful Treatment of a Patient with Drug-Refractory Rheumatoid Arthritis-Associated Interstitial Lung Disease with Upadacitinib: A Case Report
by: Yuuya Nishii, et al.
Published: (2023-11-01) -
Hydroxychloroquine serum concentration in coronavirus disease 2019 (COVID-19) patients: a retrospective study
by: Saadi Fatima Zohra, et al.
Published: (2021-07-01) -
Hydroxychloroquine Inhibits Cardiac Conduction in Aged Patients with Nonmalaria Diseases
by: Yanting Yu, et al.
Published: (2021-04-01)